Compare DNN & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | AMRX |
|---|---|---|
| Founded | 1954 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 1998 | 2018 |
| Metric | DNN | AMRX |
|---|---|---|
| Price | $3.83 | $12.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.50 | ★ $15.60 |
| AVG Volume (30 Days) | ★ 25.0M | 1.4M |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | $403.36 | $4.48 |
| Revenue Next Year | N/A | $7.13 |
| P/E Ratio | ★ N/A | $58.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $7.02 |
| 52 Week High | $4.43 | $15.42 |
| Indicator | DNN | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 50.83 |
| Support Level | $3.31 | $12.50 |
| Resistance Level | $3.84 | $13.54 |
| Average True Range (ATR) | 0.21 | 0.48 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 50.71 | 33.95 |
Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.